Abstract:The differential cellular expression of class III -tubulin isotype (III) is reviewed in the context of human embryological development and neoplasia. As compared to somatic organs and tissues, III is abundant in the central and peripheral nervous systems (CNS and PNS) where it is prominently expressed during fetal and postnatal development. As exemplified in cerebellar and sympathoadrenal neurogenesis, the distribution of III is neuron-associated, exhibiting distinct temporospatial gradients according to t… Show more
“…Mature astrocytic markers, such as GFAP, are also described to be expressed in glioma cells [53][54][55] , although Jan et al [51] showed that the malignant progression to a higher degree of invasiveness is associated with an increase in vimentin expression and a progressive loss of GFAP. Besides the expression of immature and astrocytic cell markers, gliomas also express neuronal proteins such as β-III-tubulin [56,57] and MAP2 [58] , both indicators of a high-grade astrocytoma [58] . Similarly, the expression of progenitor and mature oligodendrocytes markers are found in gliomas/astrocytomas [59,60] , although MBP is minimally expressed in GBM [59] .…”
Neural stem cells (NSC) biology is being applied to tumor research because these cells have been shown to share key properties with cancer cells. Gliomas represent the most common brain tumor, and neural stem/progenitor cells (NSPC) or early-differentiated cell type lineages may be on its origin. Here, we identified the developmental stage of the differentiation process of NSC into astrocytes that showed the highest number of tumorigenic similarities.NSPC were grown as neurospheres and astroglial differentiation was induced during 7 days in vitro (DIV). Cellular characterization was evaluated by specific neural markers at two developmental windows, i.e. NSPC/astrocyte progenitors from neurospheres until 3 DIV, and differentiating astrocytes thereafter. Predominance of immature Sox2-positive cells was verified in the first window and a prevalence of GFAP-positive cells in the second one. We then compared some tumor-related markers in GL261 glioma cells with such differentiating periods. The early progenitor cells (until 2 DIV) were those with the closest resemblances to the glioma cell line regarding BrdU incorporation, expression of microtubule-associated protein light chain 3 and of angiogenic factors (VEGF/VEGFR2), as well as S100B release. Our results suggest that early differentiating astroglial progenitors may be more susceptible to malignant transformation.
“…Mature astrocytic markers, such as GFAP, are also described to be expressed in glioma cells [53][54][55] , although Jan et al [51] showed that the malignant progression to a higher degree of invasiveness is associated with an increase in vimentin expression and a progressive loss of GFAP. Besides the expression of immature and astrocytic cell markers, gliomas also express neuronal proteins such as β-III-tubulin [56,57] and MAP2 [58] , both indicators of a high-grade astrocytoma [58] . Similarly, the expression of progenitor and mature oligodendrocytes markers are found in gliomas/astrocytomas [59,60] , although MBP is minimally expressed in GBM [59] .…”
Neural stem cells (NSC) biology is being applied to tumor research because these cells have been shown to share key properties with cancer cells. Gliomas represent the most common brain tumor, and neural stem/progenitor cells (NSPC) or early-differentiated cell type lineages may be on its origin. Here, we identified the developmental stage of the differentiation process of NSC into astrocytes that showed the highest number of tumorigenic similarities.NSPC were grown as neurospheres and astroglial differentiation was induced during 7 days in vitro (DIV). Cellular characterization was evaluated by specific neural markers at two developmental windows, i.e. NSPC/astrocyte progenitors from neurospheres until 3 DIV, and differentiating astrocytes thereafter. Predominance of immature Sox2-positive cells was verified in the first window and a prevalence of GFAP-positive cells in the second one. We then compared some tumor-related markers in GL261 glioma cells with such differentiating periods. The early progenitor cells (until 2 DIV) were those with the closest resemblances to the glioma cell line regarding BrdU incorporation, expression of microtubule-associated protein light chain 3 and of angiogenic factors (VEGF/VEGFR2), as well as S100B release. Our results suggest that early differentiating astroglial progenitors may be more susceptible to malignant transformation.
“…29,30 The cells are fixed in 4% paraformaldehyde (158127, Sigma-Aldrich) in D-PBS (Gibco 14190, Invitrogen) for 30 min, and then permeablized/blocked in fresh permeable-blocking solution composed of 5% normal donkey serum (017-000-001, Jackson ImmunoResearch, West Grove, PA), 0.3% Triton X-100 (T9284, Sigma-Aldrich) in 1X D-PBS for 2 h at room temperature. Then, cells are incubated with mouse anti-bIII-tubulin (1:500) antibody (Chemicon MAB1637, Millipore) for overnight at 4 C, washed three times, and incubated with Cy3-labeled donkey anti-mouse IgG (1:500) (Chemicon AP192C, Millipore) for 2 h in the dark.…”
Section: Eb Formation and Differentiationmentioning
This paper reports a two-layered polydimethylsiloxane microfluidic device-Flip channel, capable of forming uniform-sized embryoid bodies (EBs) and performing stem cell differentiation within the same device after flipping the microfluidic channel. The size of EBs can be well controlled by designing the device geometries, and EBs with multiple sizes can be formed within a single device to study EB size-dependent stem cell differentiation. During operation of the device, cells are positioned in the designed positions. As a result, observation and monitoring specific population of cells can be achieved for further analysis. In addition, after flipping the microfluidic channel, stem cell differentiation from the EBs can be performed on an unconfined flat surface that is desired for various differentiation processes. In the experiments, murine embryonic stem cells (ES-D3) are cultured and formed EBs inside the developed device. The size of EBs is well controlled inside the device, and the neural differentiation is performed on the formed EBs after flipping the channel. The EB size-dependent stem cell differentiation is studied using the device to demonstrate its functions. The device provides a useful tool to study stem cell differentiation without complicated device fabrication and tedious cell handling under better-controlled microenvironments.
“…Tubulin consists of · and ß subunits. In mammals, six ß-tubulin isotypes have been identified and the complex variable patterns of their expression denote cellular and functional specificity and diversity (8).…”
Section: Introductionmentioning
confidence: 99%
“…Class III ß-tubulin (ß III) is a neuron-associated isotype that is considered to be one of the earliest neuron-associated cytoskeletal markers and is thought to play an important functional role in neuronal morphogenesis (8). ß III expression is observed throughout the lifetime from early development in the central and peripheral nervous systems and in some nerve tumors, such as high-grade gliomas (9), oligodendrogliomas (10), medulloblastomas (11), retinoblastomas (12), and pheochromocytomas (13).…”
Abstract. Tubulin is a major component of microtubules. Class III ß-tubulin (ß III) is a neuron-associated ß-tubulin isotype and expressed in the normal central and peripheral nervous systems. According to a previous study, ß III is not expressed in normal skin and squamous cell carcinoma. However, its expression has not been examined in basal cell carcinoma (BCC) of the skin. Expression of ß III was analyzed together with neural cell adhesion molecule (NCAM), chromogranin A, synaptophysin, epithelial membrane antigen (EMA) and cytokeratin (CK) 20 by immunohistochemical methods in 10 non-neoplastic skin tissues and 50 BCCs. In the normal skin, immunoreactivity to ß III was restricted to the nerve bundles in the dermis and subcutis, no positivity was shown in epithelial cells of the epidermis and skin appendages. ß III and NCAM were expressed in 50 and 68% of BCCs, respectively, predominantly periphery of tumor nests, although the distribution of both markers was not always identical. Chromogranin A, synaptophysin and CK 20 were not expressed in any of BCCs. EMA was focally expressed in only 8% of BCCs. ß III is a potential candidate for inclusion to the panel of immunohistochemical markers to distinguish small BCCs from non-neoplastic hair buds, because non-neoplastic hair follicles are not positive for ß III.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.